Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...
The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...
An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...
Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...
In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can ...
Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...
New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s ...
An elderly patient died in a clinical study of Roche Holding AG’s experimental treatment for Alzheimer’s disease, prompting changes to the trial design, although the company said overall ...